Verona Pharma appoints sector veteran as CFO
Mr. Morgan is a Chartered Accountant with close to 25 years’ financial experience, predominantly in the life sciences sector, having held both corporate and advisory senior positions.
Mr. Morgan has extensive financing expertise, having led IPOs on AIM, NASDAQ and Euronext Paris as well as having completed more than 120 transactions.
He was previously the CEO of C4X Discovery plc, a small molecule discovery and development company, where he led the company’s successful IPO on London’s AIM market in 2014.
Prior to this he co-founded uniQure, a gene therapy company, where he spent five years as CFO leading a number of equity and debt transactions, including the company’s IPO on NASDAQ in 2014.
Mr. Morgan has also held CFO roles at London listed Phytopharm, Paris listed BioAlliance Pharma and Arrow Therapeutics.
He is currently a Non-executive Director at Quethera Ltd, a private gene therapy company and was previously Non-Exec Chairman of Trino Therapeutics.
Between 1997 and 2000 he was a Director in the Ernst and Young Life Sciences M&A practice, where he founded the Life Sciences M&A team.
Prior to this he spent five years as an Assistant Director at Close Brothers Corporate Finance. ■
What to read next
LATEST MOVES FROM United Kingdom
- Silence Therapeutics appoints Annalisa Jenkins to board
- Augean appoints two directors
- Syncona appoints Robert Hutchinson as director
- Virgin Money Holdings to appoint Amy Stirling to board
- Bovis Homes appoints Mike Stansfield as director
More inside POST
Gap Q2 earnings drop 3% Earnings